Vaxcyte, Inc.

NasdaqGS PCVX

Vaxcyte, Inc. Price to Book Ratio (P/B) on January 14, 2025: 4.52

Vaxcyte, Inc. Price to Book Ratio (P/B) is 4.52 on January 14, 2025, a -4.48% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Vaxcyte, Inc. 52-week high Price to Book Ratio (P/B) is 8.37 on September 19, 2024, which is 85.37% above the current Price to Book Ratio (P/B).
Vaxcyte, Inc. 52-week low Price to Book Ratio (P/B) is 3.81 on April 25, 2024, which is -15.63% below the current Price to Book Ratio (P/B).
Vaxcyte, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 5.51.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: PCVX

Vaxcyte, Inc.

CEO	Mr. Grant E. Pickering M.B.A.
IPO Date	June 12, 2020
Location	United States
Headquarters	825 Industrial Road
Employees	254
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Key trends

Past 5 years